Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9089489 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
US9526703 | DUCHESNAY | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
US9375404 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
US9937132 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) |
Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 November, 2016
Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9566252 | DUCHESNAY | Method for the alleviation of dyspareunia in women |
Nov, 2022
(3 months ago) | |
US8772353 | DUCHESNAY | Method for enhancing the bioavalability of ospemifene |
Feb, 2024
(1 year, 9 days from now) | |
US9241915 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 9 days from now) | |
US9855224 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 9 days from now) | |
US8470890 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 9 days from now) | |
US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(2 years from now) | |
US8236861 | DUCHESNAY | Method for enhancing the bioavailablity of ospemifene |
Aug, 2026
(3 years from now) | |
US8642079 | DUCHESNAY | Solid formulations of ospemifene |
Jul, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic